Renal Urate Transport

Rheumatic Disease Clinics of North America

Volumn 32, Issue 2, 2006, Pages 313-331

  Mount, David B ^a,b,c   Kwon, Charles Y ^a,b,d   Zandi Nejad, Kambiz ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; NICOTINIC ACID; OXOACID; PYRAZINOIC ACID; URATE;

ANION EXCHANGE; CARDIOVASCULAR DISEASE; DRUG EFFECT; GLOMERULUS FILTRATION; HEART FAILURE; HEREDITY; HUMAN; HYPERTENSION; HYPERURICEMIA; KETOACIDOSIS; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; LACTIC ACIDOSIS; METABOLIC SYNDROME X; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; GOUT; HUMANS; KIDNEY TUBULES, PROXIMAL; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; URIC ACID;

EID: 33646559989     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.02.006     Document Type: Review

References (154)

1. Enomoto A., Kimura H., Chairoungdua A., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 (2002) 447-452
2. Zandi-Nejad K., Plata C., Enck A.H., et al. Slc5a8 functions as a sodium-dependent pyrazinoate and nicotinate cotransporter; implications for renal urate transport. J Am Soc Nephrol 15 (2004) 89A
3. Coady M.J., Chang M.H., Charron F.M., et al. The human tumour suppressor gene SLC5A8 expresses a Na + -monocarboxylate cotransporter. J Physiol 557 Pt 3 (2004) 719-731
4. Gopal E., Fei Y.J., Miyauchi S., et al. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J 388 Pt 1 (2005) 309-316
5. Srinivas S.R., Gopal E., Zhuang L., et al. Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). Biochem J 392 Pt 3 (2005) 655-664
6. Johnson R.J., Kang D.H., Feig D., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 41 (2003) 1183-1190
7. Nakagawa T., Mazzali M., Kang D.H., et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23 (2003) 2-7
8. Sanchez-Lozada L.G., Nakagawa T., Kang D.H., et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 15 (2006) 30-33
9. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
10. Martinon F., Petrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
11. Waring W.S., Webb D.J., and Maxwell S.R. Uric acid as a risk factor for cardiovascular disease. Q J Med 93 (2000) 707-713
12. Hare J.M., and Johnson R.J. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107 (2003) 1951-1953
13. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107 (2003) 1991-1997
14. Fam A.G. Gout, diet, and the insulin resistance syndrome. J Rheumatol 29 (2002) 1350-1355
15. Bonora E., Kiechl S., Willeit J., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47 (1998) 1643-1649
16. Nakagawa T., Hu H., Zharikov S., et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290 (2006) F625-F631
17. Wu X.W., Lee C.C., Muzny D.M., et al. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A 86 (1989) 9412-9416
18. Hediger M.A. Kidney function: gateway to a long life?. Nature 417 (2002) 393-395
19. Wu X.W., Muzny D.M., Lee C.C., et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34 (1992) 78-84
20. Ames B.N., Cathcart R., Schwiers E., et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78 (1981) 6858-6862
21. Davies K.J., Sevanian A., Muakkassah-Kelly S.F., et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235 (1986) 747-754
22. Watanabe S., Kang D.H., Feng L., et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40 (2002) 355-360
23. Oda M., Satta Y., Takenaka O., et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19 (2002) 640-653
24. Choi H.K., Mount D.B., and Reginato A.M. Pathogenesis of gout. Ann Intern Med 143 (2005) 499-516
25. Kramer H.J., Choi H.K., Atkinson K., et al. The association between gout and nephrolithiasis in men: the Health Professionals' Follow-Up Study. Kidney Int 64 (2003) 1022-1026
26. Xu P., LaVallee P.A., Lin J.J., et al. Characterization of proteins binding to E-box/Ku86 sites and function of Ku86 in transcriptional regulation of the human xanthine oxidoreductase gene. J Biol Chem 279 (2004) 16057-16063
27. Xu P., LaVallee P., and Hoidal J.R. Repressed expression of the human xanthine oxidoreductase gene. E-box and TATA-like elements restrict ground state transcriptional activity. J Biol Chem 275 (2000) 5918-5926
28. Berry C.E., and Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555 Pt 3 (2004) 589-606
29. Roch-Ramel F., and Guisan B. Renal transport of urate in humans. News Physiol Sci 14 (1999) 80-84
30. Guggino S.E., Martin G.J., and Aronson P.S. Specificity and modes of the anion exchanger in dog renal microvillus membranes. Am J Physiol 244 (1983) F612-F621
31. Martinez F., Manganel M., Montrose-Rafizadeh C., et al. Transport of urate and p-aminohippurate in rabbit renal brush-border membranes. Am J Physiol 258 5 Pt 2 (1990) F1145-F1153
32. Roch-Ramel F., Diezi-Chomety F., De Rougemont D., et al. Renal excretion of uric acid in the rat: a micropuncture and microperfusion study. Am J Physiol 230 (1976) 768-776
33. Simmonds H.A., Hatfield P.J., Cameron J.S., et al. Uric acid excretion by the pig kidney. Am J Physiol 230 (1976) 1654-1661
34. Roch-Ramel F., and Weiner I.M. Excretion of urate by the kidneys of Cebus monkeys: a micropuncture study. Am J Physiol 224 (1973) 1369-1374
35. Weiner I.M. Urate transport in the nephron. Am J Physiol 237 (1979) F85-F92
36. Fanelli Jr. G.M., Bohn D.L., and Reilly S.S. Renal urate transport in the chimpanzee. Am J Physiol 220 (1971) 613-620
37. Diamond H.S., and Paolino J.S. Evidence for a postsecretory reabsorptive site for uric acid in man. J Clin Invest 52 (1973) 1491-1499
38. Guggino S.E., and Aronson P.S. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest 76 (1985) 543-547
39. Roch-Ramel F., Wong N.L., and Dirks J.H. Renal excretion of urate in mongrel and Dalmatian dogs: a micropuncture study. Am J Physiol 231 (1976) 326-331
40. Bannasch D.L., Ryun J.R., Bannasch M.J., et al. Exclusion of galectin 9 as a candidate gene for hyperuricosuria in the Dalmatian dog. Anim Genet 35 (2004) 326-328
41. Zins G.R., and Weiner I.M. Bidirectional urate transport limited to the proximal tubule in dogs. Am J Physiol 215 (1968) 411-422
42. Yu T.F., Berger L., Kupfer S., et al. Tubular secretion of urate in the dog. Am J Physiol 199 (1960) 1199-1204
43. Gutman A.B., Yu T.F., and Berger L. Tubular secretion of urate in man. J Clin Invest 38 (1959) 1778-1781
44. Praetorius E., and Kirk J.E. Hypouricemia: with evidence for tubular elimination of uric acid. J Lab Clin Med 35 (1950) 865-868
45. Ichida K., Hosoyamada M., Hisatome I., et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 (2004) 164-173
46. Steele T.H. Urate secretion in man: the pyrazinamide suppression test. Ann Intern Med 79 (1973) 734-737
47. Weiner I.M., and Tinker J.P. Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention. J Pharmacol Exp Ther 180 (1972) 411-434
48. Davis B.B., Field J.B., Rodnan G.P., et al. Localization and pyrazinamide inhibition of distal transtubular movement of uric acid-2-C14 with a modified stop-flow technique. J Clin Invest 44 (1965) 716-721
49. Gutman A.B., and Yu T.F. A three-component system for regulation of renal excretion of uric acid in man. Trans Assoc Am Physicians 74 (1961) 353-365
50. Steele T.H., and Boner G. Origins of the uricosuric response. J Clin Invest 52 (1973) 1368-1375
51. Lemieux G., Vinay P., Gougoux A., et al. Nature of the uricosuric action of benziodarone. Am J Physiol 224 (1973) 1440-1449
52. Blomstedt J.W., and Aronson P.S. pH gradient-stimulated transport of urate and p-aminohippurate in dog renal microvillus membrane vesicles. J Clin Invest 65 (1980) 931-934
53. Kahn A.M., and Aronson P.S. Urate transport via anion exchange in dog renal microvillus membrane vesicles. Am J Physiol 244 (1983) F56-F63
54. Kahn A.M., Branham S., and Weinman E.J. Mechanism of urate and p-aminohippurate transport in rat renal microvillus membrane vesicles. Am J Physiol 245 (1983) F151-F158
55. Werner D., Martinez F., and Roch-Ramel F. Urate and p-aminohippurate transport in the brush border membrane of the pig kidney. J Pharmacol Exp Ther 252 (1990) 792-799
56. Roch-Ramel F., Werner D., and Guisan B. Urate transport in brush-border membrane of human kidney. Am J Physiol 266 5 Pt 2 (1994) F797-F805
57. Boner G., and Steele T.H. Relationship of urate and p-aminohippurate secretion in man. Am J Physiol 225 (1973) 100-104
58. Koepsell H., and Endou H. The SLC22 drug transporter family. Pflugers Arch 447 (2004) 666-676
59. Mori K., Ogawa Y., Ebihara K., et al. Kidney-specific expression of a novel mouse organic cation transporter-like protein. FEBS Lett 417 (1997) 371-374
60. Hosoyamada M., Ichida K., Enomoto A., et al. Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 15 (2004) 261-268
61. Nakashima M., Uematsu T., Kosuge K., et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42 (1992) 333-335
62. Roch-Ramel F., Guisan B., and Schild L. Indirect coupling of urate and p-aminohippurate transport to sodium in human brush-border membrane vesicles. Am J Physiol 270 1 Pt 2 (1996) F61-F68
63. Online mendelian inheritance in man. Available at. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM Accessed March 20, 2006
64. Garcia M.L., Benavides J., and Valdivieso F. Ketone body transport in renal brush border membrane vesicles. Biochim Biophys Acta 600 (1980) 922-930
65. Manganel M., Roch-Ramel F., and Murer H. Sodium-pyrazinoate cotransport in rabbit renal brush border membrane vesicles. Am J Physiol 249 3 Pt 2 (1985) F400-F408
66. Boumendil-Podevin E.F., and Podevin R.A. Nicotinic acid transport by brush border membrane vesicles from rabbit kidney. Am J Physiol 240 (1981) F185-F191
67. Goldfinger S., Klinenberg Jr. E., and Seegmiller J.E. Renal retention of uric acid induced by infusion of beta-hydroxybutyrate and acetoacetate. N Engl J Med 272 (1965) 351-355
68. Padova J., and Bendersky G. Hyperuricemia in diabetic ketoacidosis. N Engl J Med 267 (1962) 530-534
69. Lieber C.S., Jones D.P., Losowsky M.S., et al. Interrelation of uric acid and ethanol metabolism in man. J Clin Invest 41 (1962) 1863-1870
70. Fanelli Jr. G.M., Bohn D., and Stafford S. Functional characteristics of renal urate transport in the Cebus monkey. Am J Physiol 218 (1970) 627-636
71. Choi H.K., Atkinson K., Karlson E.W., et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363 (2004) 1277-1281
72. Gibson H.V., and Doisy E.A. A note on the effect of some organic acids upon the uric acid excretion of man. J Biol Chem 55 (1923) 605-610
73. Michael S.T. The relation of uric acid excretion to blood lactic acid in man. Am J Physiol 141 (1944) 71-74
74. Harding V.J., Allin K.D., and Eagles B.A. The influence of fat and carbohydrate diets upon the level of blood uric acid. J Biol Chem 74 (1927) 631-643
75. Drenick E.J. Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation. Arthritis Rheum 8 (1965) 988-997
76. Shah P., and Isley W.L. Ketoacidosis during a low-carbohydrate diet. N Engl J Med 354 (2006) 97-98
77. Gershon S.L., and Fox I.H. Pharmacologic effects of nicotinic acid on human purine metabolism. J Lab Clin Med 84 (1974) 179-186
78. Shapiro M., and Hyde L. Hyperuricemia due to pyrazinamide. Am J Med 23 (1957) 596-599
79. Akalin E., Chandrakantan A., Keane J., et al. Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion. Am J Kidney Dis 37 (2001) E8
80. Barac-Nieto M., Murer H., and Kinne R. Lactate-sodium cotransport in rat renal brush border membranes. Am J Physiol 239 (1980) F496-F506
81. Barbarat B., and Podevin R.A. Stoichiometry of the renal sodium-L-lactate cotransporter. J Biol Chem 263 (1988) 12190-12193
82. Fanelli Jr. G.M., and Weiner I.M. Pyrazinoate excretion in the chimpanzee. Relation to urate disposition and the actions of uricosuric drugs. J Clin Invest 52 (1973) 1946-1957
83. Steele T.H. Hyperuricemic nephropathies. Nephron 81 Suppl 1 (1999) 45-49
84. Yu T.F., and Gutman A.B. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 38 (1959) 1298-1315
85. Roch-Ramel F., Guisan B., and Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 280 (1997) 839-845
86. Aronoff A. Acute gouty arthritis precipitated by chlorothiazide. N Engl J Med 262 (1960) 767-769
87. Cappuccio F.P., Strazzullo P., Farinaro E., et al. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 270 (1993) 354-359
88. Perez-Ruiz F., Calabozo M., Erauskin G.G., et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 47 (2002) 610-613
89. Moriwaki Y., Yamamoto T., Tsutsumi Z., et al. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism 51 (2002) 893-895
90. Weinman E.J., Eknoyan G., and Suki W.N. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest 55 (1975) 283-291
91. Ferris T.F., and Gorden P. Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 44 (1968) 359-365
92. Ogihara T., Asano T., Ando K., et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 (2002) 872-879
93. Masuzaki H., Yamamoto H., Kenyon C.J., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112 (2003) 83-90
94. Quinones Galvan A., Natali A., Baldi S., et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 268 1 Pt 1 (1995) E1-E5
95. Muscelli E., Natali A., Bianchi S., et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9 (1996) 746-752
96. Balakrishnan V.S., Coles G.A., and Williams J.D. A potential role for endogenous adenosine in control of human glomerular and tubular function. Am J Physiol 265 4 Pt 2 (1993) F504-F510
97. Balakrishnan V.S., Coles G.A., and Williams J.D. Effects of intravenous adenosine on renal function in healthy human subjects. Am J Physiol 271 2 Pt 2 (1996) F374-F381
98. Mintz D.H., Canary J.J., Carreon G., et al. Hyperuricemia in hyperparathyroidism. N Engl J Med 265 (1961) 112-115
99. Songyang Z., Fanning A.S., Fu C., et al. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275 (1997) 73-77
100. Gisler S.M., Pribanic S., Bacic D., et al. PDZK1: I. a major scaffolder in brush borders of proximal tubular cells. Kidney Int 64 (2003) 1733-1745
101. Anzai N., Miyazaki H., Noshiro R., et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C-terminal. J Biol Chem 279 (2004) 45942-45950
102. Biber J., Gisler S.M., Hernando N., et al. PDZ interactions and proximal tubular phosphate reabsorption. Am J Physiol Renal Physiol 287 (2004) F871-F875
103. Hernando N., Wagner C.A., Gisler S.M., et al. PDZ proteins and proximal ion transport. Curr Opin Nephrol Hypertens 13 (2004) 569-574
104. Lipkowitz M.S., Leal-Pinto E., Rappoport J.Z., et al. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 107 (2001) 1103-1115
105. Jutabha P., Kanai Y., Hosoyamada M., et al. Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem 278 (2003) 27930-27938
106. Van Aubel R.A., Smeets P.H., Van Den Heuvel J.J., et al. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288 (2004) 5072-5083
107. Kahn A.M., Shelat H., and Weinman E.J. Urate and p-aminohippurate transport in rat renal basolateral vesicles. Am J Physiol 249 5 Pt 2 (1985) F654-F661
108. Werner D., and Roch-Ramel F. Indirect Na+ dependency of urate and p-aminohippurate transport in pig basolateral membrane vesicles. Am J Physiol 261 2 Pt 2 (1991) F265-F272
109. Ichida K., Hosoyamada M., Kimura H., et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 63 (2003) 143-155
110. Cha S.H., Sekine T., Fukushima J.I., et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59 (2001) 1277-1286
111. Bakhiya A., Bahn A., Burckhardt G., et al. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13 (2003) 249-256
112. Sweet D.H., Chan L.M., Walden R., et al. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na + gradient. Am J Physiol Renal Physiol 284 (2003) F763-F769
113. Aslamkhan A., Han Y.H., Walden R., et al. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol Renal Physiol 285 (2003) F775-F783
114. Eraly S.A., Vallon V., Vaughn D.A., et al. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knockout mice. J Biol Chem 281 (2006) 5072-5083
115. Reed D.R., and Price R.A. X-linkage does not account for the absence of father-son similarity in plasma uric acid concentrations. Am J Med Genet 92 (2000) 142-146
116. Yang Q., Guo C.Y., Cupples L.A., et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism 54 (2005) 1435-1441
117. Healey L.A., and Bayani-Sioson P.S. A defect in the renal excretion of uric acid in Filipinos. Arthritis Rheum 14 (1971) 721-726
118. Gibson T., Waterworth R., Hatfield P., et al. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol 23 (1984) 276-282
119. Chang H.Y., Pan W.H., Yeh W.T., et al. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 28 (2001) 1640-1646
120. Simmonds H.A., McBride M.B., Hatfield P.J., et al. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. Br J Rheumatol 33 (1994) 932-937
121. Shu-Chuan Cheng L., Chiang S.L., Tu H.P., et al. Genomewide scan for gout in taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet 75 (2004) 498-503
122. Kelley W.N., Rosenbloom F.M., Henderson J.F., et al. A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci U S A 57 (1967) 1735-1739
123. Augoustides-Savvopoulou P., Papachristou F., Fairbanks L.D., et al. Partial hypoxanthine-Guanine phosphoribosyltransferase deficiency as the unsuspected cause of renal disease spanning three generations: a cautionary tale. Pediatrics 109 (2002) E17
124. Ahmed M., Taylor W., Smith P.R., et al. Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J Biol Chem 274 (1999) 7482-7488
125. Bleyer A.J., Woodard A.S., Shihabi Z., et al. Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. Kidney Int 64 (2003) 36-42
126. Hateboer N., Gumbs C., Teare M.D., et al. Confirmation of a gene locus for medullary cystic kidney disease (MCKD2) on chromosome 16p12. Kidney Int 60 (2001) 1233-1239
127. Wolf M.T., Mucha B.E., Attanasio M., et al. Mutations of the Uromodulin gene in MCKD type 2 patients cluster in exon 4, which encodes three EGF-like domains. Kidney Int 64 (2003) 1580-1587
128. Hart T.C., Gorry M.C., Hart P.S., et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 39 (2002) 882-892
129. Rampoldi L., Caridi G., Santon D., et al. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12 (2003) 3369-3384
130. Kang D.H., Nakagawa T., Feng L., et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13 (2002) 2888-2897
131. Meyer III W.J., Gill Jr. J.R., and Bartter F.C. Gout as a complication of Bartter's syndrome. A possible role for alkalosis in the decreased clearance of uric acid. Ann Intern Med 83 (1975) 56-59
132. Wolf M.T., Dotsch J., Konrad M., et al. Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene. Pediatr Nephrol 17 (2002) 602-608
133. Bingham C., Ellard S., van't Hoff W.G., et al. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1beta gene mutation. Kidney Int 63 (2003) 1645-1651
134. Igarashi P., Shao X., McNally B.T., et al. Roles of HNF-1beta in kidney development and congenital cystic diseases. Kidney Int 68 (2005) 1944-1947
135. Li T., Walsh J.R., Ghishan F.K., and Bai L. Molecular cloning and characterization of a human urate transporter (hURAT1) gene promoter. Biochim Biophys Acta 1681 (2004) 53-58
136. Pontoglio M., Barra J., Hadchouel M., et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84 (1996) 575-585
137. Ohta T., Sakano T., Igarashi T., et al. Exercise-induced acute renal failure associated with renal hypouricaemia: results of a questionnaire-based survey in Japan. Nephrol Dial Transplant 19 (2004) 1447-1453
138. Peden D.B., Hohman R., Brown M.E., et al. Uric acid is a major antioxidant in human nasal airway secretions. Proc Natl Acad Sci U S A 87 (1990) 7638-7642
139. Vollaard N.B., Shearman J.P., and Cooper C.E. Exercise-induced oxidative stress: myths, realities and physiological relevance. Sports Med 35 (2005) 1045-1062
140. Kawabe K., Murayama T., and Akaoka I. A case of uric acid renal stone with hypouricemia caused by tubular reabsorptive defect of uric acid. J Urol 116 (1976) 690-692
141. Cheong H.I., Kang J.H., Lee J.H., et al. Mutational analysis of idiopathic renal hypouricemia in Korea. Pediatr Nephrol 20 (2005) 886-890
142. Kaneko K., Yamanobe T., Onoda M., et al. Analysis of urinary calculi obtained from a patient with idiopathic hypouricemia using micro area x-ray diffractometry and LC-MS. Urol Res 33 (2005) 415-421
143. Sorensen C.M., and Chandhoke P.S. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin North Am 31 (2002) 915-925
144. Pak C.Y., Poindexter J.R., Peterson R.D., et al. Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology 60 (2002) 789-794
145. Maalouf N.M., Cameron M.A., Moe O.W., et al. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13 (2004) 181-189
146. Sakhaee K., Adams-Huet B., Moe O.W., et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 62 (2002) 971-979
147. Abate N., Chandalia M., Cabo-Chan Jr. A.V., et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65 (2004) 386-392
148. Ombra M.N., Forabosco P., Casula S., et al. Identification of a new candidate locus for uric acid nephrolithiasis. Am J Hum Genet 68 (2001) 1119-1129
149. Gianfrancesco F., Esposito T., Ombra M.N., et al. Identification of a novel gene and a common variant associated with uric acid nephrolithiasis in a Sardinian genetic isolate. Am J Hum Genet 72 (2003) 1479-1491
150. Gianfrancesco F., Esposito T., Casu G., et al. Emergence of Talanin protein associated with human uric acid nephrolithiasis in the Hominidae lineage. Gene 339 (2004) 131-138
151. Rieselbach R.E., Sorensen L.B., Shelp W.D., et al. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med 73 (1970) 359-366
152. Boss G.R., and Seegmiller J.E. Hyperuricemia and gout. Classification, complications and management. N Engl J Med 300 (1979) 1459-1468
153. Taggart A.K., Kero J., Gan X., et al. (D)-beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280 (2005) 26649-26652
154. Tunaru S., Kero J., Schaub A., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 (2003) 352-355